<?xml version='1.0' encoding='utf-8'?>
<document id="12955290"><sentence text="Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia."><entity charOffset="0-11" id="DDI-PubMed.12955290.s1.e0" text="Fluvoxamine" /><entity charOffset="44-55" id="DDI-PubMed.12955290.s1.e1" text="haloperidol" /><pair ddi="false" e1="DDI-PubMed.12955290.s1.e0" e2="DDI-PubMed.12955290.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12955290.s1.e0" e2="DDI-PubMed.12955290.s1.e1" /></sentence><sentence text="Augmentation with low-dose fluvoxamine (50-100 mg/day) to antipsychotic treatment may improve the negative symptoms in schizophrenic patients, but involves a risk of drug-drug interaction"><entity charOffset="27-38" id="DDI-PubMed.12955290.s2.e0" text="fluvoxamine" /></sentence><sentence text=" We studied the effects of fluvoxamine on plasma concentrations of haloperidol and reduced haloperidol, and their clinical symptoms, in haloperidol treated patients"><entity charOffset="27-38" id="DDI-PubMed.12955290.s3.e0" text="fluvoxamine" /><entity charOffset="67-78" id="DDI-PubMed.12955290.s3.e1" text="haloperidol" /><entity charOffset="91-102" id="DDI-PubMed.12955290.s3.e2" text="haloperidol" /><entity charOffset="136-147" id="DDI-PubMed.12955290.s3.e3" text="haloperidol" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e0" e2="DDI-PubMed.12955290.s3.e0" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e0" e2="DDI-PubMed.12955290.s3.e1" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e0" e2="DDI-PubMed.12955290.s3.e2" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e0" e2="DDI-PubMed.12955290.s3.e3" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e1" e2="DDI-PubMed.12955290.s3.e1" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e1" e2="DDI-PubMed.12955290.s3.e2" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e1" e2="DDI-PubMed.12955290.s3.e3" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e2" e2="DDI-PubMed.12955290.s3.e2" /><pair ddi="false" e1="DDI-PubMed.12955290.s3.e2" e2="DDI-PubMed.12955290.s3.e3" /></sentence><sentence text=" Twelve schizophrenic inpatients with prevailingly negative symptoms receiving haloperidol 6 mg/day were additionally treated with incremental doses of fluvoxamine for 6 weeks (25, 75 and 150 mg/day for 2 weeks each)"><entity charOffset="79-90" id="DDI-PubMed.12955290.s4.e0" text="haloperidol" /><entity charOffset="152-163" id="DDI-PubMed.12955290.s4.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.12955290.s4.e0" e2="DDI-PubMed.12955290.s4.e0" /><pair ddi="false" e1="DDI-PubMed.12955290.s4.e0" e2="DDI-PubMed.12955290.s4.e1" /></sentence><sentence text=" Plasma drug concentrations were monitored together with clinical assessments before and after each phase of the three fluvoxamine doses"><entity charOffset="119-130" id="DDI-PubMed.12955290.s5.e0" text="fluvoxamine" /></sentence><sentence text=" Geometric mean of haloperidol concentrations during coadministration of fluvoxamine 25, 75 and 150 mg/day were 120% (95%CI; 114-127%), 139% (95%CI; 130-149%), and 160% (95%CI; 142-178%) of those before fluvoxamine coadministration, respectively"><entity charOffset="19-30" id="DDI-PubMed.12955290.s6.e0" text="haloperidol" /><entity charOffset="73-84" id="DDI-PubMed.12955290.s6.e1" text="fluvoxamine" /><entity charOffset="203-214" id="DDI-PubMed.12955290.s6.e2" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.12955290.s6.e0" e2="DDI-PubMed.12955290.s6.e0" /><pair ddi="false" e1="DDI-PubMed.12955290.s6.e0" e2="DDI-PubMed.12955290.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12955290.s6.e0" e2="DDI-PubMed.12955290.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12955290.s6.e1" e2="DDI-PubMed.12955290.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12955290.s6.e1" e2="DDI-PubMed.12955290.s6.e2" /></sentence><sentence text=" We found positive correlations between increase in plasma haloperidol concentrations and plasma fluvoxamine concentrations"><entity charOffset="59-70" id="DDI-PubMed.12955290.s7.e0" text="haloperidol" /><entity charOffset="97-108" id="DDI-PubMed.12955290.s7.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.12955290.s7.e0" e2="DDI-PubMed.12955290.s7.e0" /><pair ddi="false" e1="DDI-PubMed.12955290.s7.e0" e2="DDI-PubMed.12955290.s7.e1" /></sentence><sentence text=" Scores in negative symptoms were significantly reduced after fluvoxamine coadministration, whereas no changes were observed in the other psychiatric symptoms or any subgrouped side effects"><entity charOffset="62-73" id="DDI-PubMed.12955290.s8.e0" text="fluvoxamine" /></sentence><sentence text=" Therefore, this study indicates that fluvoxamine increases plasma haloperidol concentrations in a dose-dependent manner"><entity charOffset="38-49" id="DDI-PubMed.12955290.s9.e0" text="fluvoxamine" /><entity charOffset="67-78" id="DDI-PubMed.12955290.s9.e1" text="haloperidol" /><pair ddi="false" e1="DDI-PubMed.12955290.s9.e0" e2="DDI-PubMed.12955290.s9.e0" /><pair ddi="false" e1="DDI-PubMed.12955290.s9.e0" e2="DDI-PubMed.12955290.s9.e1" /></sentence><sentence text=" However, relatively small elevations in haloperidol concentration did not lead to the development of extrapyramidal symptoms under the conditions of this study"><entity charOffset="41-52" id="DDI-PubMed.12955290.s10.e0" text="haloperidol" /></sentence><sentence text="" /></document>